The Mexican dream on ice, come true
Donovan Carrillo once again took over the court. This time in Milan, with a black suit that screamed charisma and a smile that he has not lost since he was eight years old. The stage was his from the first moment.
Under the immortal chords of Elvis Presley, a choreography designed by Benoit Richard began. But this went beyond technique. Every movement, every turn, was loaded with deep meaning.
“Each movement, full of emotion and precision, was dedicated to his maternal grandmother”
There is the key. It wasn’t just about impressing the jury, but about honoring those who always believed in those melodies. That gives their performance an extra layer, one that separates great athletes from those who simply execute.
An evolution that inspires a continent
Coming second in the ultimate final is already a monumental achievement. Carrillo transformed those four minutes into a declaration of principles: constant growth pays. It has become a reference not only for Mexico, but for all of Latin America.
The public support was immediate. The fans filled the building to see the man from Guadalajara inspire and, in the process, raise the flag high. That energy is felt even through the screen.
Their routine began with triple and double jumps that set the tone. But what really conquered the world was that lethal combination: iron concentration and contagious joy. He never seems to forget why he started this.
At the end, the gesture said it all: he kissed the ice in gratitude. He raised his arms not only in celebration, but in recognition of the path he had traveled. Their coaches nodded, knowing they had witnessed something special.
The numbers confirmed what the eyes already saw: 143.50 points in free skate and a accumulated score of 219.06. They are not just figures; They are the reflection of a season of hard work and constant evolution.
Donovan Carrillo doesn’t just compete; tells a story about ice. And in Milan, he wrote one of his best chapters, consolidating himself as the undisputed protagonist heading into 2026.
